<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019822</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2016-01827</org_study_id>
    <nct_id>NCT03019822</nct_id>
  </id_info>
  <brief_title>Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing</brief_title>
  <acronym>LAM</acronym>
  <official_title>Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation
      on empathy, mood perception, and amygdala activity to fearful stimuli. In addition, we
      predict associations between subjective effects/alterations in emotion processing tests and
      functional imaging (fMRI) activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emotional enhancement as determined by fMRI</measure>
    <time_frame>12 hours</time_frame>
    <description>Emotional enhancement (empathy, oxytocin, mood perception, fMRI amygdala blood oxygen level-dependent (BOLD) signal reactivity to fearful stimuli)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI brain activity</measure>
    <time_frame>1 hour</time_frame>
    <description>Associations between subjective effects/alterations in emotion processing with fMRI amygdala BOLD activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting State fMRI</measure>
    <time_frame>1 hour</time_frame>
    <description>Association between emotional enhancement and resting state fMRI neuronal activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect Modulation by personality traits (assessed with questionnaires),</measure>
    <time_frame>12 hours</time_frame>
    <description>Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect Modulation by amygdala reactivity to fear (assessed in the fMRI)</measure>
    <time_frame>12 hours</time_frame>
    <description>Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect Modulation by genetic polymorphisms (determined by genotyping of each subject)</measure>
    <time_frame>12 hours</time_frame>
    <description>Effect modulation by personality traits (assessed with questionnaires), baseline amygdala reactivity to fear in the fMRI, and genetic polymorphisms determined by genotyping of each subject</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo, LSD, d-Amphetamine, MDMA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD, d-Amphetamine, MDMA, Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-Amphetamine, MDMA, LSD, Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDMA, LSD, Placebo, d-Amphetamine,,</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>100ug per os, single dose</description>
    <arm_group_label>Placebo, LSD, d-Amphetamine, MDMA</arm_group_label>
    <arm_group_label>LSD, d-Amphetamine, MDMA, Placebo</arm_group_label>
    <arm_group_label>d-Amphetamine, MDMA, LSD, Placebo</arm_group_label>
    <arm_group_label>MDMA, LSD, Placebo, d-Amphetamine,,</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>125mg per os, single dose</description>
    <arm_group_label>Placebo, LSD, d-Amphetamine, MDMA</arm_group_label>
    <arm_group_label>LSD, d-Amphetamine, MDMA, Placebo</arm_group_label>
    <arm_group_label>d-Amphetamine, MDMA, LSD, Placebo</arm_group_label>
    <arm_group_label>MDMA, LSD, Placebo, d-Amphetamine,,</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphetamine</intervention_name>
    <description>40.3mg per os, single dose</description>
    <arm_group_label>Placebo, LSD, d-Amphetamine, MDMA</arm_group_label>
    <arm_group_label>LSD, d-Amphetamine, MDMA, Placebo</arm_group_label>
    <arm_group_label>d-Amphetamine, MDMA, LSD, Placebo</arm_group_label>
    <arm_group_label>MDMA, LSD, Placebo, d-Amphetamine,,</arm_group_label>
    <other_name>d-amphetamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing mannitol looking identical to the other drugs</description>
    <arm_group_label>Placebo, LSD, d-Amphetamine, MDMA</arm_group_label>
    <arm_group_label>LSD, d-Amphetamine, MDMA, Placebo</arm_group_label>
    <arm_group_label>d-Amphetamine, MDMA, LSD, Placebo</arm_group_label>
    <arm_group_label>MDMA, LSD, Placebo, d-Amphetamine,,</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 25 and 50 years.

          2. Sufficient understanding of the German language

          3. Subjects understand the procedures and the risks associated with the study.

          4. Participants must be willing to adhere to the protocol and sign the consent form.

          5. Participants must be willing to refrain from taking illicit psychoactive substances
             during the study.

          6. Participants must be willing to drink only alcohol-free liquids and no coffee, black
             or green tea, or energy drink after midnight of the evening before the study session,
             as well as during the study day.

          7. Participants must be willing not to drive a traffic vehicle or to operate machines
             within 48 h after substance administration.

          8. Women of childbearing potential must have a negative pregnancy test at the beginning
             of the study. Pregnancy tests are repeated before each study session. Women and men
             must agree to use an effective form of birth control (double-barrier method).

          9. Body mass index 18-29 kg/m2.

        Exclusion Criteria:

          1. Chronic or acute medical condition

          2. Hypertension (&gt;140/90 mmHg) or Hypotension (SBP&lt;85 mmHg)

          3. Current or previous major psychiatric disorder

          4. Psychotic disorder in first-degree relatives

          5. Illicit substance use (with the exception of cannabis) more than 10 times or any time
             within the previous two months.

          6. Pregnant or nursing women.

          7. Participation in another clinical trial (currently or within the last 30 days)

          8. Use of medications that may interfere with the effects of the study medications (any
             psychiatric medications).

          9. fMRI related criteria including: metal implants (clips from operations, cochlea, large
             red/yellow tattoos in the neck area)

         10. Tobacco smoking (&gt;10 cigarettes/day)

         11. Consumption of alcoholic drinks (&gt;10/week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <phone>+ 41 61 265 2525 Zentrale</phone>
    <email>matthias.liechti@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick C Dolder, PhD Student</last_name>
    <email>patrick.dolder@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias E Liechti, MD, MAS</last_name>
      <phone>+ 41 61 265 2525 Zentrale</phone>
      <email>matthias.liechti@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
    <mesh_term>Lysergic Acid Diethylamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

